Century Therapeutics (IPSC) Operating Expenses (2020 - 2026)

Century Therapeutics (IPSC) has reported Operating Expenses for 7 consecutive years, with $23.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 32.31% year-over-year to $23.7 million; the TTM figure through Mar 2026 stood at $115.1 million (down 21.98% YoY), while the FY2025 annual figure was $126.4 million, down 12.64% from the prior year.
• Operating Expenses improved to $23.7 million in Q1 2026 per IPSC's latest filing, from $20.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $44.0 million in Q4 2023 and bottomed at $20.7 million in Q4 2025.
• Historically, Operating Expenses has averaged $34.3 million across 5 years, with a median of $35.0 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 113.12% — and 2025, when it slumped 50.19%.
• Century Therapeutics' Operating Expenses stood at $33.8 million in 2022, then jumped by 30.16% to $44.0 million in 2023, then dropped by 5.84% to $41.5 million in 2024, then plunged by 50.19% to $20.7 million in 2025, then increased by 14.69% to $23.7 million in 2026.
• Business Quant data shows IPSC's Operating Expenses at $23.7 million in Q1 2026, $20.7 million in Q4 2025, and $36.1 million in Q3 2025.